Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio
Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, has closed a further round of investment. The £550K funding round was led by Cambridge Enterprise and five angel investors – all of whom followed initial seed investments made in April 2018. Joining the original investors is biotech entrepreneur and founder member of the Cambridge Angels, Dr Andy Richards CBE.
Stem cells are revolutionising medicine by enabling new approaches for disease modelling, precision medicine and development of new therapeutics. University of Cambridge spin-out, Qkine, uses proprietary technologies and protein engineering techniques to produce exceptionally high-purity growth factors and cytokines. Qkine’s technologies enable it to solve scientific challenges such as structural heterogeneity, poor stability and solubility and spurious interactions with other biomolecules, and provide more reliable tools for research and bio-manufacturing.
The investment enables Qkine to establish its UK manufacturing base at Cambridge Science Park, fuel the expansion of its research team and further develop its active R&D pipeline.
Commenting on his investment, Jim Warwick, Angel Investor and Chairman, Qkine said:
“Following my initial investment in Qkine was a no-brainer – its growth factors are developed from a genuinely differentiating technology, the market for these reagents is growing rapidly and the company’s founders have great, complementary skill sets.”
Dr Andy Richards added:
“Catherine (Elton) and team have done a great job at Qkine, I am excited to join their investors in this round as they move to their new facility, scale up their team, extend their R&D pipeline and expand their commercial ambitions. The need for quality and reproducibility in stem cell biology and exciting new areas such as organoids is driving a growing market that Qkine is uniquely positioned to satisfy.”
Qkine is also delighted to welcome Dr Christine Martin, Investment Manager (Life Sciences), Cambridge Enterprise to the board. Christine commented:
“Cambridge Enterprise is pleased to support Qkine as it takes its next steps. The need for high quality cytokines and growth factors continues to expand, and Qkine is poised to meet the demand with a catalogue of products to support research into stem cell, organoid and regenerative medicine applications.”